Advertisement

Supply chain firms to discuss effects of UDI mandate

By Adam Rubenfire  |  July 23, 2016

A federal mandate to use unique device identifiers offers an opportunity to reduce the risk of patients being harmed by products, but the UDI system, which is being implemented over the next four years by the Food and Drug Administration, means a lot of changes— especially for the...

Pfizer tops Q1 forecasts on higher sales, lower taxes

By Associated Press  |  May 03, 2016

Pfizer easily beat Wall Street expectations as the biggest U.S. drugmaker's first-quarter net income jumped 27% due to higher sales, a lower tax bill and some one-time gains. The company raised its 2016 financial forecasts, citing the strong quarter and an improved business outlook.

Allergan, Pfizer call off proposed $160B merger

By Associated Press  |  April 06, 2016

The biggest U.S.-based drugmaker, Pfizer, will stay put thanks to aggressive new Treasury Department rules that succeeded in discouraging Pfizer's plan to acquire rival Allergan and move to Ireland—on paper—to reduce its tax bill.

FDA approves biosimilar of J&J's money maker Remicade

By Associated Press  |  April 05, 2016

The approval of Inflectra Tuesday is only the second time that the FDA has approved a quasi-generic version of a biotech drug for the U.S. market. Remicade, a medicine for inflammatory diseases, had $6.56 billion in sales last year.

Allergan shares tumble on new tax inversion rules

By Associated Press  |  April 05, 2016

Allergan's stock is down nearly 20% in pre-market Tuesday trading after the U.S. announced an aggressive push in its campaign to shut down so-called tax inversions by American companies.

Pfizer adds $784.6M charge for Protonix deal to Q4 results

By Associated Press  |  February 16, 2016

Drugmaker Pfizer swung to a fourth-quarter financial loss, instead of a modest profit, as a result of a just-announced charge to settle a long-running federal case over reimbursements for its former blockbuster heartburn pill.

Senator scrutinizes pharma links on government pain panel

Senator scrutinizes pharma links on government pain panel

By Associated Press  |  February 08, 2016

Sen. Ron Wyden says he has "a number of concerns" about how panelists were selected and screened for an advisory panel on pain issues that includes government experts, outside academics and patient advocates.

Dealmaking keeps up heady pace

By Melanie Evans  |  January 23, 2016

Last year ended as frenzied as it began for healthcare dealmakers. Globally, merger and acquisition activity reached record volume in 2015, and the value of global healthcare deals increased 66% last year to $723.7 billion, according to Dealogic.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.